June 23, 2025 04:25 PM EDTUpdated 1 hour ago
R&D

Am­gen plans more grad­ual Mar­i­Tide dos­ing in Phase 3 

Nicole DeFeudis

Editor

Am­gen plans on re­duc­ing the start­ing dose and high­est tar­get dose of its long-act­ing obe­si­ty shot Mar­i­Tide for Phase 3, the com­pa­ny an­nounced Mon­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

The pol­i­tics of vac­ci­na­tion take cen­ter stage as RFK Jr.’s re­built CDC pan­el is set to meet

Hims and No­vo Nordisk part­ner to of­fer dis­count­ed We­govy

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

As­traZeneca, Dai­ichi Sankyo gain lung can­cer in­di­ca­tion for En­her­tu suc­ces­sor

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times